522 related articles for article (PubMed ID: 11315605)
21. [131I]metaiodobenzylguanidine in neuroblastoma patients at diagnosis.
Mastrangelo R; Lasorella A; Troncone L; Rufini V; Iavarone A; Riccardi R
J Nucl Biol Med (1991); 1991; 35(4):252-4. PubMed ID: 1823829
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis and treatment of neuroblastoma using 131I-meta-iodobenzylguanidine.
Edeling CJ; Büchler Frederiksen P; Kamper J; Jeppesen P
Nuklearmedizin; 1986 Oct; 25(5):172-5. PubMed ID: 3797256
[TBL] [Abstract][Full Text] [Related]
23. Total-body scintigraphy with 131I-meta-iodobenzylguanidine for detection of neuroblastoma.
Hoefnagel CA; Voûte PA; de Kraker J; Marcuse HR
Diagn Imaging Clin Med; 1985; 54(1):21-7. PubMed ID: 3918823
[TBL] [Abstract][Full Text] [Related]
24. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.
Matthay KK; Panina C; Huberty J; Price D; Glidden DV; Tang HR; Hawkins RA; Veatch J; Hasegawa B
J Nucl Med; 2001 Nov; 42(11):1713-21. PubMed ID: 11696644
[TBL] [Abstract][Full Text] [Related]
25. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.
Castellani MR; Chiti A; Seregni E; Bombardieri E
Q J Nucl Med; 2000 Mar; 44(1):77-87. PubMed ID: 10932604
[TBL] [Abstract][Full Text] [Related]
26. No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.
Vaidyanathan G; Zhao XG; Strickland DK; Zalutsky MR
J Nucl Med; 1997 Feb; 38(2):330-4. PubMed ID: 9025764
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.
McCluskey AG; Mairs RJ; Tesson M; Pimlott SL; Babich JW; Gaze MN; Champion S; Boyd M
J Nucl Med; 2012 Jul; 53(7):1146-54. PubMed ID: 22689924
[TBL] [Abstract][Full Text] [Related]
28. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
[TBL] [Abstract][Full Text] [Related]
29. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma.
Buckley SE; Chittenden SJ; Saran FH; Meller ST; Flux GD
J Nucl Med; 2009 Sep; 50(9):1518-24. PubMed ID: 19713562
[TBL] [Abstract][Full Text] [Related]
30. Nuclear medicine therapy of neuroblastoma.
Hoefnagel CA
Q J Nucl Med; 1999 Dec; 43(4):336-43. PubMed ID: 10731784
[TBL] [Abstract][Full Text] [Related]
31. Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans.
Monsieurs M; Brans B; Bacher K; Dierckx R; Thierens H
Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1581-7. PubMed ID: 12458391
[TBL] [Abstract][Full Text] [Related]
32. [131I]metaiodobenzylguanidine therapy after conventional therapy for neuroblastoma.
Hoefnagel CA; Voûte PA; De Kraker J; Valdés Olmos RA
J Nucl Biol Med (1991); 1991; 35(4):202-6. PubMed ID: 1823819
[TBL] [Abstract][Full Text] [Related]
33. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.
Mairs RJ; Cunningham SH; Russell J; Armour A; Owens J; McKellar K; Gaze MN
J Nucl Med; 1995 Jun; 36(6):1088-95. PubMed ID: 7769433
[TBL] [Abstract][Full Text] [Related]
34. [131I meta-iodobenzylguanidine in combination with hyperbaric oxygen therapy in the treatment of prognostically high-risk forms of neuroblastoma].
Stanková J; Kavan P; Krízová H; Hermanská E; Dosel P; Sázel M
Cas Lek Cesk; 2001 Jan; 140(1):13-7. PubMed ID: 11242978
[TBL] [Abstract][Full Text] [Related]
35. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.
Willegaignon J; Crema KP; Oliveira NC; Pelissoni RA; Coura-Filho GB; Sapienza MT; Buchpiguel CA
Clin Nucl Med; 2018 Aug; 43(8):572-578. PubMed ID: 29916922
[TBL] [Abstract][Full Text] [Related]
36. 131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma.
DuBois SG; Matthay KK
Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):53-65. PubMed ID: 23474635
[TBL] [Abstract][Full Text] [Related]
37. 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients.
Garaventa A; Bellagamba O; Lo Piccolo MS; Milanaccio C; Lanino E; Bertolazzi L; Villavecchia GP; Cabria M; Scopinaro G; Claudiani F; De Bernardi B
Br J Cancer; 1999 Dec; 81(8):1378-84. PubMed ID: 10604736
[TBL] [Abstract][Full Text] [Related]
38. Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity.
Vaidyanathan G; Friedman HS; Keir ST; Zalutsky MR
Br J Cancer; 1996 May; 73(10):1171-7. PubMed ID: 8630274
[TBL] [Abstract][Full Text] [Related]
39. L1-CAM-targeted antibody therapy and (177)Lu-radioimmunotherapy of disseminated ovarian cancer.
Fischer E; Grünberg J; Cohrs S; Hohn A; Waldner-Knogler K; Jeger S; Zimmermann K; Novak-Hofer I; Schibli R
Int J Cancer; 2012 Jun; 130(11):2715-21. PubMed ID: 21796623
[TBL] [Abstract][Full Text] [Related]
40. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
Kang TI; Brophy P; Hickeson M; Heyman S; Evans AE; Charron M; Maris JM
J Pediatr Hematol Oncol; 2003 Oct; 25(10):769-73. PubMed ID: 14528098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
